Revolution Medicines (RVMD) Earnings Date & Reports

Key Takeaways

• Revolution Medicines will report third-quarter 2026 results on Wednesday, November 4, 2026, after the market close, followed by a conference call at 4:30 p.m. ET.
• Wall Street consensus points to a net loss of roughly $2.34 per share, wider than the $1.61 per share loss in the same quarter a year ago.
• This is the company's first full quarter operating with an approved product, making early RASONQUE launch metrics a central focus.
• Revolution Medicines has missed consensus earnings estimates in each of its last eight reported quarters.
• Management raised its full-year 2026 operating expense guidance to a range of $1.7 billion to $1.8 billion, reflecting higher clinical and launch spending.
• For additional context on RVMD's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for deeper insight into the stock's activity and outlook.
• You can also explore Trending AI Robots to see AI-driven trading strategies currently gaining traction across the market.

Earnings Context and Why It Matters

Revolution Medicines is a commercial-stage oncology company focused on RAS-addicted cancers, and its third-quarter 2026 report carries unusual weight because it follows the U.S. Food and Drug Administration (FDA) approval of RASONQUE (elironrasib) in late August 2026. That approval transformed the company from a pre-revenue developer into a commercial organization. As a result, investors will be looking beyond the headline net loss for early signals of launch execution, pricing, and market access. The report also lands against a backdrop of sharply rising spending as the company advances late-stage programs such as daraxonrasib and zoldonrasib, making cost discipline and cash runway key investor concerns.

Earnings Expectations

Analysts expect Revolution Medicines to report a net loss of approximately $2.34 per share for the third quarter of 2026, compared with a loss of $1.61 per share in the prior-year period. Consensus revenue estimates sit near $24 million, reflecting the earliest contributions from the RASONQUE launch. The company has not beaten consensus earnings estimates in its last eight quarters, and its most recent result was a $3.06 per share loss that fell short of expectations. Investors will watch research and development (R&D) spending, operating expenses, and the cash balance, which stood at roughly $1.9 billion as of March 31, 2026, before more than $2 billion in net proceeds from April 2026 financing.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings season names like RVMD, it offers a structured way to surface candidates matching specific criteria.

Market Reaction and Investor Sentiment

Sentiment heading into the report is mixed. The stock has gained significantly year to date, but its pattern of wider-than-expected losses and an estimated negative post-earnings drift since its August 2026 report underscore the sensitivity of this event. Key risk factors include the pace of RASONQUE's commercial ramp, the trajectory of operating expenses, and any updates to pipeline timelines. Because Revolution Medicines remains unprofitable and is funding an expansive clinical portfolio, investors are especially attuned to cash burn and management's commentary on how long the current balance sheet can support development.

Forward Outlook and Key Factors to Monitor

Following the third-quarter report, investors should focus on several forward-looking themes rather than the headline loss alone. First, watch for management's early commentary on RASONQUE launch metrics, including prescriber adoption, reimbursement, and any initial revenue contribution. These details will offer the first concrete read on commercial execution.

Second, pay attention to spending guidance. The company has already raised its full-year 2026 operating expense outlook, and any further revisions will signal how aggressively it is investing in late-stage trials for daraxonrasib and zoldonrasib. Rising R&D and commercial costs are expected, but the rate of increase matters for long-term cash runway.

Finally, monitor pipeline updates and upcoming data catalysts. As a clinical-stage-to-commercial transition story, the stock's valuation remains tied to development milestones and regulatory progress across its RAS(ON) inhibitor portfolio. Balance-sheet strength and disciplined execution will be central to how investors interpret the path forward.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations